In­tro­duc­ing End­points FDA+, our new pre­mi­um week­ly reg­u­la­to­ry news re­port led by Zachary Bren­nan

CRLs. 483s. CBER, CDER and RWE. For bio­phar­ma pro­fes­sion­als, these acronyms com­mand at­ten­tion be­cause of the fun­da­men­tal role FDA plays in drug de­vel­op­ment. Now End­points is dou­bling down on reg­u­la­to­ry cov­er­age, and launch­ing a week­ly re­port fo­cus­ing on de­vel­op­ments out of White Oak, with analy­sis and in­sight in­to what it all means.

Cov­er­age will be led by our new se­nior ed­i­tor, Zachary Bren­nan. He joins End­points from POLITI­CO, where he cov­ered phar­ma. Pri­or to that he was the man­ag­ing ed­i­tor for Reg­u­la­to­ry Fo­cus, a news pub­li­ca­tion from the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER